Trevi Therapeutics Overview
- Founded
- 2011

- Status
- Public
- Employees
- 26

- Stock Symbol
- TRVI

- Share Price
- $1.52
- (As of Monday Closing)
Trevi Therapeutics General Information
Description
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
Contact Information
- 195 Church Street
- 14th Floor
- New Haven, CT 06510
- United States
Trevi Therapeutics Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.52 | $1.26 | $0.46 - $2.96 | $32.6M | 25.8M | 611K | -$1.76 |
Trevi Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
---|---|---|---|---|
EV | 8,260 | 5,270 | 3,743 | |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (33,991) | (32,451) | (26,821) | (20,628) |
Net Income | (34,943) | (32,758) | (26,050) | (20,545) |
Total Assets | 31,596 | 47,131 | 60,001 | 10,526 |
Total Debt | 14,502 | 14,211 | 356 | 46 |
Trevi Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Trevi Therapeutics‘s full profile, request access.
Request a free trialTrevi Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Trevi Therapeutics‘s full profile, request access.
Request a free trialTrevi Therapeutics Comparisons
Industry
000000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialTrevi Therapeutics Competitors (22)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Adynxx | Formerly VC-backed | San Francisco, CA | 0 | 0000 | 000000000000 | 0000 |
00000000 000000000 | Corporation | Henderson, NV | 000 | 00000 | 000000 - 000 | 00000 |
000000 00000000000 | Formerly VC-backed | Salt Lake City, UT | 0000 | 000000000 - | ||
00000 000000000000 | Venture Capital-Backed | San Diego, CA | 00 | 0000 | 000000 - 000 | 0000 |
00000000 | Venture Capital-Backed | San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
Trevi Therapeutics Patents
Trevi Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3106995-A1 | Treatment of chronic cough, breathlessness and dyspnea | Pending | 23-Jul-2018 | 0000000000 | |
AU-2019309913-A1 | Treatment of chronic cough, breathlessness and dyspnea | Pending | 23-Jul-2018 | 0000000000 | |
EP-3826635-A1 | Treatment of chronic cough, breathlessness and dyspnea | Pending | 23-Jul-2018 | 0000000000 | |
US-20200022974-A1 | Treatment of chronic cough, breathlessness and dyspnea | Abandoned | 23-Jul-2018 | 0000000000 | |
EP-3820472-A1 | Treatment of the pruritic symptoms of liver disease | Pending | 11-Jul-2018 | A61K31/485 |
Trevi Therapeutics Executive Team (8)
Trevi Therapeutics Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
Anne Vanlent | Self | Board Member | 000 0000 |
Annie Mitsak Ph.D | Self | Board Member | 000 0000 |
David Meeker MD | Self | Chairman & Board Member | 000 0000 |
Dominick Colangelo | Self | Board Member | 000 0000 |
Edward Mathers | New Enterprise Associates | Board Member | 000 0000 |
Trevi Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialTrevi Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Trevi Therapeutics‘s full profile, request access.
Request a free trial